Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI)

BACKGROUND: Critical limb ischemia (CLI) is associated with increased risk of tissue loss, leading to significant morbidity and mortality. Therapeutic angiogenesis using cell-based treatments, notably mesenchymal stem cells (MSCs), is essential for enhancing blood flow to ischemic areas in subjects...

Descripción completa

Detalles Bibliográficos
Autores principales: Shirbaghaee, Zeinab, Heidari Keshel, Saeed, Rasouli, Mehdi, Valizadeh, Majid, Hashemi Nazari, Seyed Saeed, Hassani, Mohammad, Soleimani, Masoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324209/
https://www.ncbi.nlm.nih.gov/pubmed/37408043
http://dx.doi.org/10.1186/s13287-023-03390-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324209/
https://www.ncbi.nlm.nih.gov/pubmed/37408043
http://dx.doi.org/10.1186/s13287-023-03390-9

Ejemplares similares